| Trial ID: | L0104 |
| Source ID: | NCT02356419
|
| Associated Drug: |
Recombinant Erythropoietin Stimulating Protein
|
| Title: |
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Failure
|
| Interventions: |
DRUG: Recombinant erythropoietin stimulating protein
|
| Outcome Measures: |
Primary: Reticulocyte counts, observe the reticulocyte counts and judge whether rESP could improve anemia, 6 months | Secondary: Hemoglobin counts, observe the hemoglobin counts and judge whether rESP could improve anemia, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-09
|
| Completion Date: |
2015-03
|
| Results First Posted: |
|
| Last Update Posted: |
2015-02-05
|
| Locations: |
Shengjing Hospital affiliated to China Medical University, Shenyang, Liaoning, 110004, China
|
| URL: |
https://clinicaltrials.gov/show/NCT02356419
|
